| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
ARTICLES |
Thyroid Division, Brigham and Womens Hospital, Harvard Medical School, Boston Massachusetts 02115
Address all correspondence and requests for reprints to: P. Reed Larsen, M.D., Brigham and Womens Hospital, Thyroid DivisionHIM 550, 77 Avenue Louis Pasteur; Boston, Massachusetts 02115. E-mail: Larsen{at}rascal.med.harvard.edu
Type 2 iodothyronine deiodinase (D2) catalyzes the first step in thyroid hormone action, the deiodination of T4 to T3 . Endogenous D2 activity is posttranslationally regulated by substrate that accelerates its degradation through the ubiquitin-proteasome pathway. To understand how D2 activity correlates with D2 protein during its normal decay and rT3-induced down-regulation, HEK-293 cells, transiently expressing human D2, were labeled with Na75SeO3 and then treated with 100 µM cycloheximide (CX), 30 nM rT3, and/or 10 µM MG132, a specific proteasome inhibitor, for 24 h. D2 protein and enzyme activity changed in parallel, disappearing with a half-life of 2 h in the presence of CX, or 1 h when CX + rT3 were combined. Treatment with MG132 blocked these effects. We created selenocysteine (Sec) 133 to cysteine (Cys) or alanine (Ala) D2 mutants, without changing Sec 266. The CysD2 activity and protein levels were also parallel, with a similar half-life of approximately 2 h, whereas the rT3-induced D2 down-regulation required approximately 1000-fold higher rT3 concentration (30 µM) due to a proportionally higher Michaelis constant of CysD2. In similar experiments, the AlaD2 mutant retained the short half-life but was not catalytically active and not susceptible to rT3-accelerated degradation. We conclude that substrate-induced loss of D2 activity is due to proteasomal degradation of the enzyme and requires interaction with the catalytic center of the protein.
This article has been cited by other articles:
![]() |
A. M. Zavacki, R. Arrojo e Drigo, B. C. G. Freitas, M. Chung, J. W. Harney, P. Egri, G. Wittmann, C. Fekete, B. Gereben, and A. C. Bianco The E3 Ubiquitin Ligase TEB4 Mediates Degradation of Type 2 Iodothyronine Deiodinase Mol. Cell. Biol., October 1, 2009; 29(19): 5339 - 5347. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. R. Larsen Type 2 Iodothyronine Deiodinase in Human Skeletal Muscle: New Insights into Its Physiological Role and Regulation J. Clin. Endocrinol. Metab., June 1, 2009; 94(6): 1893 - 1895. [Full Text] [PDF] |
||||
![]() |
B. Gereben, A. M. Zavacki, S. Ribich, B. W. Kim, S. A. Huang, W. S. Simonides, A. Zeold, and A. C. Bianco Cellular and Molecular Basis of Deiodinase-Regulated Thyroid Hormone Signaling Endocr. Rev., December 1, 2008; 29(7): 898 - 938. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Lamirand, G. Mercier, M. Ramauge, M. Pierre, and F. Courtin Hypoxia Stabilizes Type 2 Deiodinase Activity in Rat Astrocytes Endocrinology, October 1, 2007; 148(10): 4745 - 4753. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. D. V. Sagar, B. Gereben, I. Callebaut, J.-P. Mornon, A. Zeold, W. S. da Silva, C. Luongo, M. Dentice, S. M. Tente, B. C. G. Freitas, et al. Ubiquitination-Induced Conformational Change within the Deiodinase Dimer Is a Switch Regulating Enzyme Activity Mol. Cell. Biol., July 1, 2007; 27(13): 4774 - 4783. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. S Wagner, S. M Wajner, J. M Dora, and A. L. Maia Regulation of Dio2 gene expression by thyroid hormones in normal and type 1 deiodinase-deficient C3H mice J. Endocrinol., June 1, 2007; 193(3): 435 - 444. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. A. Christoffolete, R. Arrojo e Drigo, F. Gazoni, S. M. Tente, V. Goncalves, B. S. Amorim, P. R. Larsen, A. C. Bianco, and A. M. Zavacki Mice with Impaired Extrathyroidal Thyroxine to 3,5,3'-Triiodothyronine Conversion Maintain Normal Serum 3,5,3'-Triiodothyronine Concentrations Endocrinology, March 1, 2007; 148(3): 954 - 960. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. P Peeters, W. M van der Deure, and T. J Visser Genetic variation in thyroid hormone pathway genes; polymorphisms in the TSH receptor and the iodothyronine deiodinases. Eur. J. Endocrinol., November 1, 2006; 155(5): 655 - 662. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. E. Silva Thermogenic Mechanisms and Their Hormonal Regulation Physiol Rev, April 1, 2006; 86(2): 435 - 464. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Yasuo, N. Nakao, S. Ohkura, M. Iigo, S. Hagiwara, A. Goto, H. Ando, T. Yamamura, M. Watanabe, T. Watanabe, et al. Long-Day Suppressed Expression of Type 2 Deiodinase Gene in the Mediobasal Hypothalamus of the Saanen Goat, a Short-Day Breeder: Implication for Seasonal Window of Thyroid Hormone Action on Reproductive Neuroendocrine Axis Endocrinology, January 1, 2006; 147(1): 432 - 440. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Debaveye, B. Ellger, L. Mebis, E. Van Herck, W. Coopmans, V. Darras, and G. Van den Berghe Tissue Deiodinase Activity during Prolonged Critical Illness: Effects of Exogenous Thyrotropin-Releasing Hormone and Its Combination with Growth Hormone-Releasing Peptide-2 Endocrinology, December 1, 2005; 146(12): 5604 - 5611. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Martinez-deMena and M.-J. Obregon Insulin increases the adrenergic stimulation of 5' deiodinase activity and mRNA expression in rat brown adipocytes; role of MAPK and PI3K J. Mol. Endocrinol., February 1, 2005; 34(1): 139 - 151. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. P. Peeters, A. W. van den Beld, H. van Toor, A. G. Uitterlinden, J. A. M. J. L. Janssen, S. W. J. Lamberts, and T. J. Visser A Polymorphism in Type I Deiodinase Is Associated with Circulating Free Insulin-Like Growth Factor I Levels and Body Composition in Humans J. Clin. Endocrinol. Metab., January 1, 2005; 90(1): 256 - 263. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Yasuzawa-Amano, N. Toyoda, A. Maeda, A. Kosaki, Y. Mori, T. Iwasaka, and M. Nishikawa Expression and Regulation of Type 2 Iodothyronine Deiodinase in Rat Aorta Media Endocrinology, December 1, 2004; 145(12): 5638 - 5645. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. W. J. S. Wassen, W. Klootwijk, E. Kaptein, D. J. Duncker, T. J. Visser, and G. G. J. M. Kuiper Characteristics and Thyroid State-Dependent Regulation of Iodothyronine Deiodinases in Pigs Endocrinology, September 1, 2004; 145(9): 4251 - 4263. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. H. Stipanuk, L. L. Hirschberger, M. P. Londono, C. L. Cresenzi, and A. F. Yu The ubiquitin-proteasome system is responsible for cysteine-responsive regulation of cysteine dioxygenase concentration in liver Am J Physiol Endocrinol Metab, March 1, 2004; 286(3): E439 - E448. [Abstract] [Full Text] |
||||
![]() |
B. W. Kim, A. M. Zavacki, C. Curcio-Morelli, M. Dentice, J. W. Harney, P. R. Larsen, and A. C. Bianco Endoplasmic Reticulum-Associated Degradation of the Human Type 2 Iodothyronine Deiodinase (D2) is Mediated via an Association between Mammalian UBC7 and the Carboxyl Region of D2 Mol. Endocrinol., December 1, 2003; 17(12): 2603 - 2612. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Botero, B. Gereben, C. Goncalves, L. A. de Jesus, J. W. Harney, and A. C. Bianco Ubc6p and Ubc7p Are Required for Normal and Substrate-Induced Endoplasmic Reticulum-Associated Degradation of the Human Selenoprotein Type 2 Iodothyronine Monodeiodinase Mol. Endocrinol., September 1, 2002; 16(9): 1999 - 2007. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. Gereben, A. Kollar, J. W. Harney, and P. R. Larsen The mRNA Structure Has Potent Regulatory Effects on Type 2 Iodothyronine Deiodinase Expression Mol. Endocrinol., July 1, 2002; 16(7): 1667 - 1679. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. G. J. M. Kuiper, W. Klootwijk, and T. J. Visser Substitution of Cysteine for a Conserved Alanine Residue in the Catalytic Center of Type II Iodothyronine Deiodinase Alters Interaction with Reducing Cofactor Endocrinology, April 1, 2002; 143(4): 1190 - 1198. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. C. Bianco, D. Salvatore, B. Gereben, M. J. Berry, and P. R. Larsen Biochemistry, Cellular and Molecular Biology, and Physiological Roles of the Iodothyronine Selenodeiodinases Endocr. Rev., February 1, 2002; 23(1): 38 - 89. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Peeters, C. Fekete, C. Goncalves, G. Legradi, H. M. Tu, J. W. Harney, A. C. Bianco, R. M. Lechan, and P. R. Larsen Regional physiological adaptation of the central nervous system deiodinases to iodine deficiency Am J Physiol Endocrinol Metab, July 1, 2001; 281(1): E54 - E61. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. M. Yen Physiological and Molecular Basis of Thyroid Hormone Action Physiol Rev, July 1, 2001; 81(3): 1097 - 1142. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. Gereben, D. Salvatore, J. W. Harney, H. M. Tu, and P. R. Larsen The Human, but Not Rat, dio2 Gene Is Stimulated by Thyroid Transcription Factor-1 (TTF-1) Mol. Endocrinol., January 1, 2001; 15(1): 112 - 124. [Abstract] [Full Text] |
||||
![]() |
C. Buettner, J. W. Harney, and P. R. Larsen The Role of Selenocysteine 133 in Catalysis by the Human Type 2 Iodothyronine Deiodinase Endocrinology, December 1, 2000; 141(12): 4606 - 4612. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. Gereben, C. Goncalves, J. W. Harney, P. R. Larsen, and A. C. Bianco Selective Proteolysis of Human Type 2 Deiodinase: A Novel Ubiquitin-Proteasomal Mediated Mechanism for Regulation of Hormone Activation Mol. Endocrinol., November 1, 2000; 14(11): 1697 - 1708. [Abstract] [Full Text] |
||||
![]() |
C. Curcio, M. M. A. Baqui, D. Salvatore, B. H. Rihn, S. Mohr, J. W. Harney, P. R. Larsen, and A. C. Bianco The Human Type 2 Iodothyronine Deiodinase Is a Selenoprotein Highly Expressed in a Mesothelioma Cell Line J. Biol. Chem., August 3, 2001; 276(32): 30183 - 30187. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Endocrinology | Endocrine Reviews | J. Clin. End. & Metab. |
| Molecular Endocrinology | Recent Prog. Horm. Res. | All Endocrine Journals |